Carolyn Sampson
Family Medicine · Goldsboro, NCNPI 1841280401
Payments from drug & device makers
Across 122 payments — averaging $29.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$447
- Lilly USA, LLC$372
- AstraZeneca$247
- Pfizer$188
- GSK$168
- plus $900 from 19 others
What the payments were for
- Food & beverage$3,548100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $1,226 |
| Amgen | 8 | $447 |
| Lilly USA, LLC | 11 | $372 |
| AstraZeneca | 5 | $247 |
| Pfizer | 7 | $188 |
| GSK | 6 | $168 |
| AbbVie | 8 | $135 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 5 | $68 |
| Abbott | 3 | $60 |
| Johnson & Johnson | 3 | $57 |
| Boehringer Ingelheim | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Merck | 3 | $46 |
| Exact Sciences | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,548 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 16 | $18,764 |
| LinzessLinaclotide | 14 | $15,685 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $1,646 |
| SynthroidLevothyroxine Sodium | 15 | $1,423 |
| Atorvastatin Calcium | 155 | $1,221 |
| FenofibrateFenofibrate Nanocrystallized | 31 | $1,196 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,030 |
| Gabapentin | 44 | $1,013 |
| Ventolin HfaAlbuterol Sulfate | 17 | $962 |
| Fluticasone Propionate | 66 | $778 |
| Levothyroxine Sodium | 96 | $773 |
| Metoprolol Succinate | 55 | $770 |
| Omeprazole | 59 | $729 |
| Lisinopril | 70 | $718 |
| Pantoprazole Sodium | 65 | $716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $52 | $18,76416 claims |
| AbbVieLinzess, Synthroid | $135 | $17,10829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Goldsboro
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.